Haemonetics Co. (NYSE:HAE) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Haemonetics Co. (NYSE:HAE) have been assigned a consensus rating of “Moderate Buy” from the nine analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $101.67.

HAE has been the topic of a number of recent analyst reports. JMP Securities cut their target price on shares of Haemonetics from $125.00 to $100.00 and set a “market outperform” rating on the stock in a research note on Friday, February 7th. Bank of America lowered shares of Haemonetics from a “neutral” rating to an “underperform” rating and cut their target price for the company from $95.00 to $68.00 in a research note on Friday, February 7th. Barrington Research cut their target price on shares of Haemonetics from $108.00 to $95.00 and set an “outperform” rating on the stock in a research note on Friday, February 7th. Raymond James restated a “strong-buy” rating and issued a $115.00 target price (down previously from $120.00) on shares of Haemonetics in a research note on Friday, February 7th. Finally, JPMorgan Chase & Co. started coverage on shares of Haemonetics in a research note on Friday, December 6th. They issued an “overweight” rating and a $116.00 target price on the stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Global Alpha Capital Management Ltd. bought a new position in Haemonetics in the 3rd quarter worth about $806,000. Loomis Sayles & Co. L P grew its position in Haemonetics by 8.1% in the 3rd quarter. Loomis Sayles & Co. L P now owns 163,856 shares of the medical instruments supplier’s stock worth $13,171,000 after purchasing an additional 12,310 shares during the last quarter. BNP Paribas Financial Markets grew its position in Haemonetics by 174.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 16,949 shares of the medical instruments supplier’s stock worth $1,362,000 after purchasing an additional 10,774 shares during the last quarter. Westfield Capital Management Co. LP grew its position in Haemonetics by 10.9% in the 3rd quarter. Westfield Capital Management Co. LP now owns 823,663 shares of the medical instruments supplier’s stock worth $66,206,000 after purchasing an additional 80,783 shares during the last quarter. Finally, Boston Trust Walden Corp grew its position in Haemonetics by 13.1% in the 4th quarter. Boston Trust Walden Corp now owns 915,722 shares of the medical instruments supplier’s stock worth $71,500,000 after purchasing an additional 106,114 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Haemonetics Stock Performance

NYSE:HAE opened at $65.77 on Thursday. The company has a debt-to-equity ratio of 1.35, a current ratio of 3.97 and a quick ratio of 2.55. The firm has a 50-day moving average of $69.15 and a two-hundred day moving average of $75.56. The stock has a market cap of $3.30 billion, a P/E ratio of 25.89, a PEG ratio of 1.11 and a beta of 0.43. Haemonetics has a 1-year low of $58.80 and a 1-year high of $97.97.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 6th. The medical instruments supplier reported $1.19 earnings per share for the quarter, missing analysts’ consensus estimates of $1.20 by ($0.01). Haemonetics had a net margin of 9.47% and a return on equity of 23.66%. On average, research analysts expect that Haemonetics will post 4.55 earnings per share for the current fiscal year.

About Haemonetics

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.